Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Carcinoma, Non-Small-Cell Lung 4Recurrence 2Esophageal Neoplasms 2Carcinoma, Hepatocellular 2Solid Tumors Harboring NTRK Fusion 1Pancreatic Neoplasms 1Liver Neoplasms 1Insulin-Like Growth Factor I, Resistance To 1Advanced Solid Tumor 1

Interventions

pembrolizumab 11Injections 10tislelizumab 7Nivolumab 4Irinotecan 4Cetuximab 4cediranib 3Paclitaxel 3PM 01183 3Leucovorin 3Gemcitabine 3Fluorouracil 3Cisplatin 3toripalimab 2spartalizumab 2serabelisib 2olaparib 2glumetinib 2camrelizumab 2apatinib 2adagrasib 2Therapeutics 2Pemetrexed 2Oxaliplatin 2Midazolam 2Drug Therapy 2Docetaxel 2Digoxin 2Cyclophosphamide 2Carboplatin 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Advanced Solid Tumor × Receptor Protein-Tyrosine Kinases × Clear all
NCT04866641 2025-05-30

Safety and Tolerability Study for T-1201 Injection 100 mg Kit in Patients With Advanced Solid Tumors

Taivex Therapeutics Corporation

Phase 1 Recruiting
40 enrolled
Other solid neoplasm

Advanced Solid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡